References
- CuferTOvcaricekTO’BrienMESystemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-yearsEur J Cancer20134961216122523265700
- LacoutureMEMechanisms of cutaneous toxicities to EGFR inhibitorsNat Rev Cancer200661080381216990857
- OrdituraMDe VitaFGaliziaGCorrelation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysisOncol Rep20092141023102819288004
- JonkerDJO’CallaghanCJKarapetisCSCetuximab for the treatment of colorectal cancerN Engl J Med2007357202040204818003960
- WackerBNagraniTWeinbergJWittKClarkGCagnoniPJCorrelation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studiesClin Cancer Res200713133913392117606725
- TakataTTarutaniMZouboulisCCSanoSSebaceous glands as the primary target of EGFR-inhibitors in the development of papulopustular eruptionJ Dermatol Sci201266216516822440861
- Guttman-YasskyEMitaADe JongeMCharacterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinibEur J Cancer201046112010201920621734
- LichtenbergerBMGerberPAHolcmannMEpidermal EGFR controls cutaneous host defense and prevents inflammationSci Transl Med20135199199ra111
- MasciaFLamGKeithCGenetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapySci Transl Med20135199199ra110
- IwataCAkimotoNSatoTMorokumaYItoAAugmentation of lipogenesis by 15-deoxy-Delta12,14-prostaglandin J2 in hamster sebaceous glands: identification of cytochrome P-450-mediated 15-deoxy-Delta12,14-prostaglandin J2 productionJ Invest Dermatol2005125586587216297182
- AlestasTGancevicieneRFimmelSMüller-DeckerKZouboulisCCEnzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glandsJ Mol Med (Berl)2006841758716388388